

**OPTN Ad Hoc Disease Transmission Advisory Committee
PHS Revisions Work Group
Meeting Summary
February 28, 2020
Conference Call**

**Marian Michaels, MD, MPH, FAST, Chair
Ricardo La Hoz, MD, FACP, FAST, Vice Chair**

Introduction

The PHS Revisions Work Group Subcommittee met via Citrix GoToTraining teleconference on 02/28/2020 to discuss the following agenda items:

1. OPTN Project Overview and Timeline: Revisions to PHS Guidelines for Increased Risk Organ Designation
2. Open Forum/Questions

The following is a summary of the Subcommittee's discussions.

1. OPTN Project Overview and Timeline: Revisions to PHS Guidelines for Increased Risk Organ Designation

DTAC chair presented the project overview and timeline.

Data summary:

Slides attached.

Summary of discussion:

Committee member was concerned that we may not have enough information for the OPTN Policy and Oversight Committee (POC) at this point. UNOS staff explained that the workgroup just needs to request permission to begin work on the project once the PHS guidelines are published, to revise OPTN guidelines to be in alignment with PHS guidelines, as per the Final Rule. At this point, the subcommittee does not need to present on the exact changes being introduced.

Next steps:

DTAC Vice Chair presenting project to the OPTN Policy Oversight Committee on March 26. Work will begin after the publication of the PHS revised guidelines, expected between March-May 2020.

2. Open Forum/Questions

DTAC chair opened the floor for any questions from subcommittee members.

Summary of discussion:

CDC representative informed the committee that there may be a slight delay in release of the PHS guidelines, due to the prioritization of the response to COVID-19. The committee will adjust the timeline for OPTN release of guidelines in accordance with CDC release.

Multiple committee members were concerned about how OPTN revisions would affect tissue and blood banks. Discussed that tissue and blood banks are under the jurisdiction of the FDA, even though many

organ procurement agencies also procure tissues. Also discussed how there is a fundamental difference between organ, tissue, and blood procurement due to the acuity of organ shortage.

Next steps:

HRSA will continue communication on OPTN guideline revisions with the American Academy of Blood Banks (AABB) and the American Academy of Tissue Banks (AATB). DTAC chair will also communicate with the infectious disease specialist on the board of the AABB.

Upcoming Meetings

- Further meetings will be scheduled once the CDC publishes the PHS guidelines, expected between March-May 2020

Attendance

- **Subcommittee Members**
 - Emily Blumberg
 - Maria Casarella
 - Lara Danziger-Isakov
 - Catherine Kling
 - Sarah Koohmaraie
 - Ricardo La Hoz
 - Marian Michaels
 - Jennifer Reese
 - Diesa Samp
 - Nicole Theodoropoulos
 - R. Patrick Wood
- **HRSA Representatives**
 - Jim Bowman
 - Marilyn Levi
 - Chris McLaughlin
- **UNOS Staff**
 - Nicole Benjamin
 - Darby Harris
 - Courtney Jett
 - Leah Slife
 - Susan Tlusty
 - Emily Ward
- **CDC Staff**
 - Sridhar Basavarju